title: Efficacy and safety of a cisplatin and paclitaxel induction regimen followed by chemoradiotherapy for patients with locally advanced head and neck squamous cell carcinoma.
abstract: The purpose of this phase II trial was to evaluate the tolerability, safety, and efficacy of a non-5-fluorouracil (5-FU)-based induction chemotherapy followed by chemoradiotherapy (CRT) for patients with locally advanced head and neck squamous cell carcinoma (HNSCC).
  
  
  
  Sixty patients with stage III to IV HNSCC were treated with induction paclitaxel and cisplatin (TP; paclitaxel 175 mg/m(2) and cisplatin 80 mg/m(2) , 3 cycles) followed by CRT (cisplatin 100 mg/m(2) ; D1, 22, and 43 of radiotherapy).
  
  
  
  Fifty-six patients (93.3%) completed 3 cycles of induction TP (no treatment-related deaths), 52 (86.7%) completed definitive CRT per protocol (adverse event [AE] grade ≥2 in 53.3%). The overall response rate after induction TP was 82.5% for patients with resectable disease and 55.5% for unresectable disease (p = .023), and complete response (CR) rate after CRT was 70.0% for patients with resectable disease and 30.0% for unresectable disease (p = .005).
  
  
  
  Induction TP followed by cisplatin based-CRT was well-tolerated, safe, and had high overall response rate in selected patients with locally advanced HNSCC. © 2015 Wiley Periodicals, Inc. Head Neck 38: E970-E980, 2016.
authors.affiliation: Department of Medical Oncology, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.
authors.forename: Luciano
authors.initials: L
authors.lastname: de Souza Viana
authors.affiliation: Department of Medical Oncology, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.
authors.forename: Felipe Coelho
authors.initials: FC
authors.lastname: de Aguiar Silva
authors.affiliation: Department of Medical Oncology, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.
authors.forename: Alexandre
authors.initials: A
authors.lastname: Andrade Dos Anjos Jacome
authors.affiliation: Department of Medical Oncology, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.
authors.forename: Danielle
authors.initials: D
authors.lastname: Calheiros Campelo Maia
authors.affiliation: Department of Radiotherapy, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.
authors.forename: Marcos
authors.initials: M
authors.lastname: Duarte de Mattos
authors.affiliation: Department of Radiotherapy, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.
authors.forename: Alexandre
authors.initials: A
authors.lastname: Arthur Jacinto
authors.affiliation: Department of Radiotherapy, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.
authors.forename: Augusto
authors.initials: A
authors.lastname: Elias Mamere
authors.affiliation: Department of Head and Neck Surgery, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.
authors.forename: Domingos
authors.initials: D
authors.lastname: Boldrini Junior
authors.affiliation: Department of Head and Neck Surgery, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.
authors.forename: Renato
authors.initials: R
authors.lastname: de Castro Capuzzo
authors.affiliation: Department of Head and Neck Surgery, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.
authors.forename: Carlos
authors.initials: C
authors.lastname: Roberto Santos
authors.affiliation: Department of Head and Neck Surgery, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.
authors.forename: Andre
authors.initials: A
authors.lastname: Lopes Carvalho
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000628:therapy*; D059248:Chemoradiotherapy; D002945:Cisplatin / Q000627:therapeutic use*; D005260:Female; D005472:Fluorouracil; D006258:Head and Neck Neoplasms / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000627:therapeutic use*; D011446:Prospective Studies
chemical_list: D017239:Paclitaxel; D002945:Cisplatin; D005472:Fluorouracil
keywords: chemoradiation therapy; head and neck cancer; induction chemotherapy; organ preservation; squamous cell carcinoma